Marstacimab for People with Severe Hemophilia A or Moderate to Severe Hemophilia B Without Inhibitors: A Plain Language Summary of Publication of the BASIS Study
Therapeutic Advances in Hematology · 2026-04 · 17
DOI: 10.1177/20406207261430259 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Hematology, online erschienen am 28.04.2026. Verfasst von Davide Matino und 18 weiteren Autor:innen. Beteiligte Einrichtung: Thrombosis and Atherosclerosis Research Institute, McMaster University, and Department of Medicine, McMaster University, Hamilton, ON, Canada. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
What is this summary about? This is a summary of the results from a clinical study of treatment for people with severe hemophilia A or moderately severe to severe hemophilia B without inhibitors. Because severe hemophilia A and B predominantly affect men and boys, this study only included men and boys aged 12 to 74 years. The study was published in Blood . People with hemophilia either have low amounts of clotting factors or are missing certain clotting factors in their blood. There are medicines that people with hemophilia can take to replace the missing clotting factor. These medicines must be injected into a vein and are usually given more than once a week. Marstacimab is an antibody that works by attaching to a protein in the blood called tissue factor pathway inhibitor (or TFPI). TFPI works separately from clotting factors. Marstacimab helps the balance between blood flowing freely and clotting. Marstacimab is given by a simple injection under the skin (not in a vein or muscle) and can be taken less often than clotting factors. Marstacimab may offer a new way to help people with hemophilia. What were the results of the study? The study showed that men with hemophilia had fewer treated bleed events during 1 year with marstacimab treatment compared to previous factor replacement therapy. The researchers reported that marstacimab was safe and most side effects were mild to moderate. What do the results mean? These studies showed that marstacimab could help prevent bleeding in men with hemophilia A or B, without inhibitors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Thrombosis and Atherosclerosis Research Institute, McMaster University, and Department of Medicine, McMaster University, Hamilton, ON, Canada.
- Pfizer Inc, Collegeville, PA, USA.
- Pfizer Inc, New York, NY, USA.
- Pfizer Inc, Cambridge, MA, USA.
- Cohen Children's Medical Center, Northwell Hemostasis and Thrombosis Center, Northwell Health, New Hyde Park, NY, USA.
- Department of Molecular Medicine and Haematology, University of the Witwatersrand, National Health Laboratory Service, Johannesburg, South Africa.
Förderung
- Pfizer
Zitieren
APA
Matino, D., Palladino, A., Taylor, C. T., Hwang, E., Raje, S., Nayak, S., McDonald, R., Acharya, S. S., Mahlangu, J., Jimenez-Yuste, V., Choraria, N., Yang, R., Li, C. K., Al-Khabori, M., Wali, Y., Adrian, J. M., Park, Y. S., Zülfikar, O. B., & Teeter, J. (2026). Marstacimab for People with Severe Hemophilia A or Moderate to Severe Hemophilia B Without Inhibitors: A Plain Language Summary of Publication of the BASIS Study. Therapeutic Advances in Hematology, 17. https://doi.org/10.1177/20406207261430259
Vancouver
Matino D, Palladino A, Taylor CT, Hwang E, Raje S, Nayak S, et al. Marstacimab for People with Severe Hemophilia A or Moderate to Severe Hemophilia B Without Inhibitors: A Plain Language Summary of Publication of the BASIS Study. Therapeutic Advances in Hematology. 2026;17. doi:10.1177/20406207261430259
BibTeX
@article{Matino2026,
author = {Matino, Davide and Palladino, Andrew and Taylor, Carrie Turich and Hwang, Eunhee and Raje, Sangeeta and Nayak, Satyaprakash and McDonald, Regina and Acharya, Suchitra S and Mahlangu, Johnny and Jimenez-Yuste, Victor and Choraria, Nirmalkumar and Yang, Renchi and Li, Chi Kong and Al-Khabori, Murtadha and Wali, Yasser and Adrian, Javier Morales and Park, Young-Shil and Zülfikar, O Bülent and Teeter, John},
title = {Marstacimab for People with Severe Hemophilia A or Moderate to Severe Hemophilia B Without Inhibitors: A Plain Language Summary of Publication of the BASIS Study},
journal = {Therapeutic Advances in Hematology},
year = {2026},
volume = {17},
doi = {10.1177/20406207261430259}
}
EUVIMED